Intelligence · Clinical Development
Pipeline search results
Programs matching “radiation” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 59 pipeline programs matching "radiation" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
20240178
Amgen
Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.
1 trial -
3-dimensional conformal radiation therapy
United Therapeutics Europe Ltd
Head and Neck Cancer
1 trial -
D5160C00048
AstraZeneca AB
Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.
1 trial -
Elective nodal irradiation (ENI)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Esophageal Squamous Cell Carcinoma
1 trial -
HX-H2112345
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Radiation Proctitis
1 trial -
Individualized Elective Neck Irradiation
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Stereotactic Radiation Therapy
GT Biopharma
Brain Metastases
1 trial -
Steroid nasal spray
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Radiation-Induced Mucositis
1 trial -
Topical application of Periplaneta americana-derived Meilian Fuxin Solution
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Radiation-induced Dermatitis
1 trial -
intensity-modulated radiation therapy
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
internal mammary nodal irradiation
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
radiation therapy
United Therapeutics Europe Ltd
Bladder Cancer
1 trial -
2025-206
The First People's Hospital of Lianyungang
Radiation - Induced Proctitis
1 trial -
APHP200080
Pari Pharma GmbH
Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resection, and for the standard of care including concurrent temoradiation followed by adjuvant TMZ with or without Tumor Treating Fields*. (*Tumor Treating Fields is applicable only in participating centers in France)
1 trial -
Aflibercept
Regeneron UK Limited
Radiation Retinopathy
1 trial -
Budenofalk 4 mg Zäpfchen, placebo to test
Dr. Falk Pharma GmbH
Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma
1 trial -
Darleukin, Fibromun
Philogen S.p.A.
Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.
1 trial -
Deep-sea fish oil
The First People's Hospital of Lianyungang
Radiation Toxicity
1 trial -
Donepezil Hydrochloride
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Radiation Injuries
1 trial -
Embrace-III Hi-Risk
Disc Medicine
high risk or poor response after chemoradiation and brachytherapy for locally advanced cervix cancer
1 trial -
FirstHCMU-JBi-PARTOM
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Metastatic Castration-resistant Prostate Cancer
1 trial -
GRA.05.SPR.0001
Lacuna Pharma Pty Ltd
Radiation-induced dermatitis (radiodermatitis)
1 trial -
Gocovri (extended-release amantidine)
SUPERNUS PHARMACEUTICALS, INC.
Radiation Encephalopathy
1 trial -
Hydrogel of spirulina-derived exosomes.
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Radiation-induced Esophagitis
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.